医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Courtagen Life Sciences Inc. Enters into an Exclusive Distribution Agreement with the Alliance Global Group

2012年11月15日 PM01:25
このエントリーをはてなブックマークに追加


 

DUBAI & WOBURN, Mass.

Courtagen Life Sciences Inc. announced today they have signed an exclusive strategic distribution agreement with the Alliance Global Group (AGBL) to help clinicians in emerging markets diagnose and manage a number of genetically based disorders. Courtagen’s test menu currently offers clinical tests for mitochondrial disorders (mtSEEK™ and nucSEEK™) and a newly released panel for epilepsy and seizure (epiSEEK™). Courtagen plans to add a number of key tests for other important neurological disorders.

“Building this relationship with AGBL is a critical component of Courtagen’s international business expansion,” said Brian McKernan, CEO, Courtagen Life Sciences, Inc.

Courtagen’s CLIA Laboratory genetic tests use next generation sequencing (NGS) technology, propriety bioinformatics platform, ZiPhyr™ and state of the art analytic capabilities to accurately sequence patient’s DNA and translate the sequence data into highly useful, clinically relevant information for physicians. Additionally, Courtagen’s protein diagnostics division offers decentralized testing of protein biomarker to simplify pre-clinical and clinical trial protocols.

“We are pleased to enter into this agreement with Courtagen,” said Dr. Tamer Degheidy, CEO of Alliance Global. “Courtagen’s portfolio of genetic tests will certainly have a positive impact on patients’ diagnosis and management in markets covered by our group.”

About Courtagen Life Sciences Inc.
Based in Woburn, Massachusetts (USA), Courtagen Life Sciences is a privately held life sciences company that provides innovative proteomic and genomic products and services to the life sciences industry. Founded by innovators in next-generation sequencing, genetics, molecular biology, and information science, the company delivers tools to enable researchers and clinicians to make better decisions regarding drug development and patient care. For more information, please visit: www.courtagen.com

About Alliance Global Group (AGBL)
The AGBL Group of companies is the largest biomedical gateway to the emerging markets of Middle East, Africa and Asia. The group is dedicated to bringing the latest technologies and products to researchers, clinicians, diagnostic users and healthcare providers in the markets it covers. The group employs more than 80 specialists and has six regional offices offering distribution, consultation and product development services. The company helps biomedical technology manufacturers and suppliers introduce their products and services to emerging markets, reflecting on the healthcare standards within those markets. For more information, please visit: www.agbl.net

CONTACT

Courtagen Life Sciences Inc.
Elizabeth Holland, +1
617-892-7178
Vice President, Business Operations
Elizabeth.holland@courtagen.com
or
Alliance
Global Group

info@agbl.net

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent